The new cells prevented the onset of diabetes in an animal model of the disease bringing personalized cell therapy for diabetes closer.
Scientists at the Gladstone Institutes and the University of California, San Francisco (UCSF) have successfully converted human skin cells into fully-functional pancreatic cells. The new cells produced insulin in response to changes in glucose levels, and, when transplanted into mice, the cells protected the animals from developing diabetes in a mouse model of the disease.
The new study, published in Nature Communications, also presents significant advancements in cellular reprogramming technology, which will allow scientists to efficiently scale up pancreatic cell production and manufacture trillions of the target cells in a step-wise, controlled manner. This accomplishment opens the door for disease modeling and drug screening and brings personalized cell therapy a step closer for patients with diabetes.
“Our results demonstrate for the first time that human adult skin cells can be used to efficiently and rapidly generate functional pancreatic cells that behave similar to human beta cells,” says Matthias Hebrok, PhD, director of the Diabetes Center at UCSF and a co-senior author on the study. “This finding opens up the opportunity for the analysis of patient-specific pancreatic beta cell properties and the optimization of cell therapy approaches.”
In the study, the scientists first used pharmaceutical and genetic molecules to reprogram skin cells into endoderm progenitor cells—early developmental cells that have already been designated to mature into one of a number of different types of organs. With this method, the cells don’t have to be taken all the way back to a pluripotent stem cell state, meaning the scientists can turn them into pancreatic cells faster. The researchers have used a similar procedure previously to create heart, brain, and liver cells.
After another four molecules were added, the endoderm cells divided rapidly, allowing more than a trillion-fold expansion. Critically, the cells did not display any evidence of tumor formation, and they maintained their identity as early organ-specific cells.
The scientists then progressed these endoderm cells two more steps, first into pancreatic precursor cells, and then into fully-functional pancreatic beta cells. Most importantly, these cells protected mice from developing diabetes in a model of disease, having the critical ability to produce insulin in response to changes in glucose levels.
“This study represents the first successful creation of human insulin-producing pancreatic beta cells using a direct cellular reprogramming method,” says first author Saiyong Zhu, PhD, a postdoctoral researcher at the Gladstone Institute of Cardiovascular Disease. “The final step was the most unique—and the most difficult—as molecules had not previously been identified that could take reprogrammed cells the final step to functional pancreatic cells in a dish.”
Sheng Ding, PhD, a senior investigator in the Roddenberry Stem Cell Center at Gladstone and co-senior author on the study, adds, “This new cellular reprogramming and expansion paradigm is more sustainable and scalable than previous methods. Using this approach, cell production can be massively increased while maintaining quality control at multiple steps. This development ensures much greater regulation in the manufacturing process of new cells. Now we can generate virtually unlimited numbers of patient-matched insulin-producing pancreatic cells.”
The Latest on: Personalized cell therapy
via Google News
The Latest on: Personalized cell therapy
- CellPoint and Hypertrust Patient Data Care co-develop xCellit platform for cell therapies at the point-of-careon November 30, 2021 at 5:00 am
CellPoint and Hypertrust Patient Data Care (HPDC) today announced the launch of xCellit. The xCellit system was co-developed to make autologous cell therapies available more rapidly and efficiently by ...
- Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in Chinaon November 29, 2021 at 7:00 pm
Collaboration highlights the value of MRD solid tumor data generated by Genetron’s Mutation Capsule platform, and further accelerates product developmentBEIJING, Nov. 30, 2021 (GLOBE NEWSWIRE) -- ...
- Custom Shop Rough Crafts Delivers BMW R 18 Berlin Barnstormeron November 29, 2021 at 12:56 pm
Winston Yeh takes his talents to Bavaria. Rough Crafts headman Winston Yeh is an auteur in today’s custom motorcycle scene. Whether he’s tricking out a Yamaha XSR 900 or reimagining a Royal Enfield ...
- VIDEO: Use of liquid biopsy critical for personalized therapy in NSCLCon November 24, 2021 at 10:26 am
Charu Aggarwal, MD, MPH, spoke with Healio about a presentation she gave at this year’s Chemotherapy Foundation Symposium.Aggarwal, Leslye M. Heisler assistant professor for lung cancer excellence at ...
- Artificial intelligence tool predicts treatment response and survival in small cell lung cancer patientson November 24, 2021 at 10:03 am
Researchers at the Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University have used artificial intelligence (AI) to identify patterns on computed ...
- AI identifies patterns on CT scans that offer new promise for treating small cell lung canceron November 23, 2021 at 3:12 pm
Researchers at the Center for Computational Imaging and Personalized Diagnostics at Case Western Reserve University have used artificial intelligence (AI) to identify patterns on computed tomography ...
- Red Cell Forms Zephyr AI to Revolutionize Drug Discovery and Precision Medicineon November 22, 2021 at 6:02 am
Red Cell Partners (“Red Cell”), an investment and incubation firm that backs, builds, and scales technology-led companies in healthcare and defense, today announced the formation of Zephyr AI, Inc.
- Personalized T-Cell Immunotherapy for Children’s Brain Tumorson November 19, 2021 at 4:00 am
The study is reportedly the first to create a new workflow for neoantigen identification that incorporates both genetic sequencing and protein identification to create a personalized treatment for ...
- Researchers Report Promising Strategy to Develop Personalized Therapy for Neuroblastomaon November 18, 2021 at 10:40 am
Using cell cultures from pediatric patients with neuroblastoma, researchers performed drug-response testing and investigated correlations between copy number and cytotoxicity of drug treatment.
- Personalized T cell immunotherapy for pediatric brain tumors is one step closer to becoming a realityon November 18, 2021 at 2:00 am
Children's National Hospital experts developed a new approach that discovered unique proteins in an individual tumor's cells, which then helped scientists generate personalized T cells to target and ...
via Bing News